ATLANTA – Transcatheter aortic valve replacement (TAVR) with operator’s choice of prosthesis was noninferior to surgical aortic valve replacement (SAVR) concerning the composite of all-cause mortality or stroke at 1 year in patients with severe, symptomatic aortic stenosis at low to intermediate surgical risk, new randomized trial data show.